JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, inclu…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 4.90 | 4.04 | 3.85 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 100.00 | 3.05 | 0.00 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 100.00 | 4.09 | 0.00 | |
| Cash | 100.00 | 2.46 | 0.00 | |
| Capex | -100.00 | -0.01 | 0.00 | |
| Free Cash Flow | -100.00 | -0.40 | 0.00 | |
| Revenue | 100.00 | 0.21 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 100.00 | 0.50 | 0.00 | |
| Operating Margin | -100.00 | -3.04 | 0.00 | |
| ROA | n.A. | -0.18 | n.A. | |
| ROE | n.A. | -0.23 | n.A. | |
| ROIC | n.A. | -0.13 | n.A. | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 2126.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 2126.HK is permitted for members.
6
Leverage & Liquidity